Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 10/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18232514 | 0.83 | DPP4 (0.35) | DPP4BACE1KCNH2BACE2 | |
| SCHEMBL18232490 | 0.80 | CA2 (0.39) | CA2OPRM1OPRK1MAP4K4 | |
| SCHEMBL18235892 | 0.79 | BACE1 (0.42) | DPP4CA2BACE1BACE2 | |
| SCHEMBL18235895 | 0.76 | MAOA (0.36) | DPP4CA2BACE1KCNH2BACE2 | |
| SCHEMBL21799844 | 0.74 | CA2 (0.44) | DPP4CA2OPRM1OPRK1 | |
| SCHEMBL10203575 | 0.74 | MEN1 (0.36) | CA2 | |
| SCHEMBL19102996 | 0.74 | SMN1; SMN2 (0.41) | BACE1BACE2 | |
| SCHEMBL13527770 | 0.73 | LOXL2 (0.42) | DPP4 | |
| SCHEMBL765514 | 0.72 | ALDH1A1 (0.35) | CA2BACE1KCNH2OPRM1OPRK1 | |
| SCHEMBL172639 | 0.70 | MPO (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | DPP4 2444/4885CA2 4318/4885BACE1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.